Priorities for Improving the Management of Gastroenteropancreatic ...
The FNIH partnership with the Neuroendocrine Tumor-Carcinoid Summit ... which are companies that market a somatostatin receptor analog for the ... Tumours of
the midgut ( jejunum, ileum and ascending colon, including carcinoid syndrome).
... Survival from malignant digestive endocrine tumors in England and Wales: ...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2538549/...
|
{2} Drug Sandostatin LAR Approved In Japan For Acromegaly And ...
In the western Phase III clinical trials for malignant carcinoid syndrome, data from 93 patients, in whom subcutaneous treatment with Sandostatin Injection ...
http://www.biospace.com/news_story.aspx?NewsEntityId=1585832...
|
Capsule Endoscopy
209.00 - 209.03, Malignant carcinoid tumors of the small intestine .... Alberta Heritage Foundation for Medical Research (AHFMR). Ingestible imaging capsule ...
Small-bowel tumors diagnosed by wireless capsule endoscopy: Report of five cases
. .... Capsule endoscopy for Peutz-Jeghers syndrome. MSAC Application 1119. ...
http://www.aetna.com/cpb/medical/data/500_599/0588.html...
|
Lung cancer - Wikipedia, the free encyclopedia
Small cell lung carcinoma, 16.8. Carcinoid, 0.8 ..... A number of targeted agents are at the early stages of clinical research, ... have focused their
efforts since the 1970s at marketing their product toward women and girls, ...
Malignant lung tumors made up only 1% of all cancers seen at autopsy in 1878,
...
http://en.wikipedia.org/wiki/Lung_cancer...
|
Business & Regulatory Report
naive patients with unresectable malignant pleural mesothelioma. AstraZeneca ( NYSE: AZN) said it has ..... Rare post-marketing reports of anaphylactic shock
and angioedema have been reported. ... with carcinoid syndrome who are
symptomatic despite .... for clinical research for US Oncology and co-director
of ...
http://www.bcm.edu/cancercenter/?PMID=12379...
|
Medical Product List
In fulfilling that task, OOPD interacts with the medical and research communities, ... 200 drugs and biological products for rare diseases have been
brought to market since 1983. ... Chronic, Infantile, Neurological, Cutaneous,
Articular syndrome ... Primary malignant melanoma of the conjunctiva. R (Back to
Top) ...
http://rarediseases.info.nih.gov/GARD/MedicalProductList.asp...
|
Roche Annual Report 2008 - Pharmaceuticals and Diagnostics pipelines
tember enables Roche to further advance its research ... new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009
the .... malignant melanoma. I. Plexxikon a R7112. MDM2 antagonist .... anti-
VEGF monoclonal antibody high risk carcinoid ... gastroparesis, irritable bowel
syndrome ...
http://www.roche.com/gb08erd.pdf...
|
Record #: 2007-050 DATE: March 22, 2007 FROM: Carol A. Pamer, R.Ph ...
Division of Surveillance, Research and Communication Support, HFD-410 ... One Year Post-Pediatric Exclusivity Post-marketing Adverse Event Review: ....
carcinoid syndrome (24%), where Sandostatin LAR Depot dosing was 10 to 30mg once
a month.” ..... MALIGNANT NEOPLASM OF LYMPHATIC AND HEMATOPOIETIC TISSUE ...
http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4295b_0...
|
Newly Published Phase III Data Show Novartis Oncology Drug ...
1 Oct 2009 ... Research Store ... tumors are the second most common gastrointestinal malignancy after colon cancer(3). ... Functioning NET causes the symptoms of carcinoid
syndrome, .... or approved for any additional indications or labeling in any
market. ... midgut tumors: A report from the PROMID study group. ...
http://www.biospace.com/news_story.aspx?NewsEntityId=157697...
|
ICD-9-CM Coordination and Maintenance Committee Meeting September ...
The Agency for Health Research and Quality (AHRQ) is proposing the following new codes and tabular changes. .... 209.09 Malignant carcinoid tumor of other sites
of the foregut ..... Prevention (CDC) received reports of an increased number of
cases of eye infections ... voluntarily removed from the market worldwide. ...
http://www.cdc.gov/nchs/data/icd9/agendaSep07.pdf...
|
